On July 20, Everest Medicines rose 5.18% in regular trading, trading at HKD 25.96 per share, with turnover of HKD 49.26 million.

On the news front, the rebound follows a sharp biotech sector selloff on July 17, during which Everest Medicines had dropped 7.83%. The current recovery is primarily driven by a broad sector bounce, with peers Akeso up 5.94%, Remegen up 8.52%, 3SBio up 5.02%, BeiGene up 3.12%, and Innovent Bio up 3.93%, indicating clear sector-wide recovery momentum.

Multiple positive catalysts also underpin sentiment, including the recent inclusion of three Everest Medicines products in the National Essential Drug List covering infection, cardiovascular emergency, and gastrointestinal critical care, as well as the completed EVER001 licensing deal with Travere Therapeutics confirming execution capability. These factors, combined with a technical rebound from oversold conditions, collectively support the current upward movement.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)